Name: ABCIXIMAB (ReoproR)
Classification: platelet glycoprotein IIb/IIIa receptor antagonist (human monoclonal antibody)
  • inhibits platelet aggregation
  • used with heparin and aspirin as adjunct to percutaneous transluminal coronary angioplasty
Dose: IV Direct: 
  • 0.25mg/kg over at least 1 minute given 10-60 minutes before the procedure
Administration: IV Infusion: 
9 mg / 250 ml NS
  • run at 10 ug/min for 12 hours post cardiac catheterization
  • should be administered with a 0.2 micron filter
  • requires dedicated line
Adverse Effects:
 
 
 
 
 

Hematological: 
risk for complications increase in patients over 65 years, with history of GI disease or who weigh less than 75 kg

  • major bleeding incidents (intracranial, GI or retroperitoneal characterized by abdominal, back or leg pain)
  • thrombocytopenia
  • anemia, leukocytosis

Cardiovascular:

  • arrhythmias
  • hypotension
  • pericardial effusion, peripheral edema

Respiratory:

  • pleural effusion, pericarditis
  • pulmonary edema
  • pulmonary embolism
  • pneumonia


Other:

  • nausea, vomiting
  • visual distrubances
Contraindications:
  • active hemorrhage
  • active intracranial or gastrointestinal bleeding
  • severe hypertension
  • history of vasculitis
  • underlying condition and risk for bleeding must be weight against potential benefits
Caution:
  • readministration within 30 days is asoociated with more severe thrombocytopenia
Monitoring Therapy:
  • INR/PTT
  • hemoglobin
  • platelet count
  • bleeding
  • continuous heart rate and ECG rhythm
  • blood pressure
  • CCTC Protocol:
    • May be administered IV direct or by IV infusion by an Adult Critical Care Nurse.
    • Continuous infusions must be administered by infusion device and the pump library must be enabled.


    Lynne Kelly, Pharmacist, CCTC
    Brenda Morgan, Clinical Nurse Specialist, CCTC
    Last Update: September 17, 2018

    LHSCHealth Professionals

    Last Updated September 17, 2018 | © 2007, LHSC, London Ontario Canada